Target type: molecularfunction
Binding to a C-C chemokine; C-C chemokines do not have an amino acid between the first two cysteines of the characteristic four-cysteine motif. [GOC:ai]
C-C chemokines, also known as beta chemokines, are a family of small proteins that play a critical role in the regulation of immune cell trafficking and inflammation. These chemokines exert their effects by binding to specific G protein-coupled receptors (GPCRs) expressed on the surface of immune cells. C-C chemokine binding to their cognate receptors initiates a cascade of intracellular signaling events, ultimately leading to the activation of immune cells and their directed migration towards sites of inflammation or infection.
The molecular function of C-C chemokine binding can be described in several key steps:
1. **Chemokine Binding:** The first step involves the chemokine molecule binding to its specific receptor on the target immune cell. This binding is typically characterized by high affinity and specificity, ensuring that the chemokine targets the appropriate cell type.
2. **Conformational Change and Receptor Dimerization:** Upon chemokine binding, the GPCR undergoes a conformational change, leading to the formation of receptor dimers. This dimerization is essential for the subsequent signaling events.
3. **G Protein Activation:** The activated receptor interacts with a heterotrimeric G protein, leading to the exchange of GDP for GTP on the alpha subunit of the G protein. This activation of the G protein initiates downstream signaling cascades.
4. **Second Messenger Production:** The activated G protein alpha subunit can activate various effector enzymes, such as phospholipase C (PLC), adenylate cyclase, or phosphoinositide 3-kinase (PI3K), leading to the production of second messenger molecules like inositol triphosphate (IP3), diacylglycerol (DAG), or cAMP.
5. **Calcium Signaling and Cell Activation:** These second messengers trigger a cascade of intracellular signaling events, including calcium mobilization, protein kinase activation, and cytoskeletal rearrangements.
6. **Cell Migration:** The ultimate consequence of C-C chemokine binding is the directed migration of immune cells towards the source of the chemokine. This migration is driven by changes in cell adhesion, cytoskeletal dynamics, and chemotaxis.
In summary, C-C chemokine binding to their receptors on immune cells initiates a complex signaling pathway that ultimately leads to cell activation and migration. This process is essential for the regulation of immune responses, the recruitment of immune cells to sites of inflammation, and the resolution of infection.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| C-X-C chemokine receptor type 1 | A C-X-C chemokine receptor type 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25024] | Homo sapiens (human) |
| C-X-C chemokine receptor type 3 | A C-X-C chemokine receptor type 3 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P49682] | Homo sapiens (human) |
| C-C chemokine receptor type 8 | A C-C chemokine receptor type 8 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P51685] | Homo sapiens (human) |
| C-X-C chemokine receptor type 2 | A C-X-C chemokine receptor type 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25025] | Homo sapiens (human) |
| Atypical chemokine receptor 3 | An atypical chemokine receptor 3 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25106] | Homo sapiens (human) |
| C-C chemokine receptor type 4 | A C-C chemokine receptor type 4 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P51679] | Homo sapiens (human) |
| C-C chemokine receptor type 2 | A C-C chemokine receptor type 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P41597] | Homo sapiens (human) |
| C-C chemokine receptor type 9 | A C-C chemokine receptor type 9 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P51686] | Homo sapiens (human) |
| C-X-C chemokine receptor type 4 | A C-X-C chemokine receptor type 4 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P61073] | Homo sapiens (human) |
| C-C chemokine receptor type 5 | A C-C chemokine receptor type 5 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P51681] | Homo sapiens (human) |
| C-C chemokine receptor type 3 | A C-C chemokine receptor type 3 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P51677] | Homo sapiens (human) |
| C-C chemokine receptor type 1 | A C-C chemokine receptor type 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P32246] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| 1,10-phenanthroline | 1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases | phenanthroline | EC 2.7.1.1 (hexokinase) inhibitor; EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor |
| 2,2'-dipyridyl | 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'. 2,2'-Dipyridyl: A reagent used for the determination of iron. | bipyridine | chelator; ferroptosis inhibitor |
| amiodarone | amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias. Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. | 1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound | cardiovascular drug |
| clotrimazole | conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes | antiinfective agent; environmental contaminant; xenobiotic | |
| diclofenac | diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position. Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. | amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound | antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic |
| disulfiram | organic disulfide; organosulfur acaricide | angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor | |
| fasudil | fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia. fasudil: intracellular calcium antagonist; structure in first source | isoquinolines; N-sulfonyldiazepane | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent |
| indomethacin | indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis. Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. | aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole | analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic; xenobiotic metabolite |
| iproniazid | carbohydrazide; pyridines | ||
| itraconazole | piperazines | ||
| nifedipine | Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. | C-nitro compound; dihydropyridine; methyl ester | calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent |
| rofecoxib | butenolide; sulfone | analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug | |
| terfenadine | Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME. | diarylmethane | |
| dibenzothiazyl disulfide | dibenzothiazol-2-yl disulfide : An organic disulfide resulting from the formal oxidative coupling of the thiol groups of two molecules of 1,3-benzothiazole-2-thiol. It is used as an accelerator in the rubber industry. dibenzothiazyl disulfide: vulcanizing accelerant | benzothiazoles; organic disulfide | allergen |
| 1-naphthylisothiocyanate | 1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage. | isothiocyanate | insecticide |
| 4,4'-dimethyl-2,2'-bipyridine | 4,4'-dimethyl-2,2'-bipyridine: structure in first source | ||
| 5,5'-dimethyl-2,2'-bipyridyl | 5,5'-dimethyl-2,2'-bipyridyl: structure in first source | bipyridines | |
| benzetimide | piperidines | ||
| zalcitabine | zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase. Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. | pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor |
| selegiline | Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl. | selegiline; terminal acetylenic compound | geroprotector |
| dexibuprofen | dexibuprofen: structure in first source | ibuprofen | non-narcotic analgesic; non-steroidal anti-inflammatory drug |
| plerixafor | plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2 | azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound | anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant |
| neocuproine | neocuproine : A member of the class of phenanthrolines that is 1,10-phenanthroline bearing two methyl substituents at positions 2 and 9. neocuproine: Spectrophotometric determination of copper and ultramicro blood sugar determinations; structure; RN given refers to parent cpd | phenanthrolines | chelator; copper chelator |
| benzylaniline | benzylaniline: major metabolite of antazoline; RN given refers to parent cpd | ||
| 2,2',2''-terpyridine | 2,2',2''-terpyridine: RN given refers to parent cpd 2,2':6',2''-terpyridine : A tridentate heterocyclic ligand that binds metals at three meridional sites giving two adjacent 5-membered MN2C2 chelate rings. | terpyridines | chelator |
| 5-methyl-1,10-phenanthroline | |||
| 3,4,7,8-tetramethyl-1,10-phenanthroline | |||
| terephthalamide | benzenedicarboxamide | ||
| benzoyltyrosine ethyl ester | ethyl N-benzoyl-L-tyrosinate : An L-tyrosine derivative that is the ethyl ester of N-benzoyltyrosine. | benzamides; ethyl ester; L-tyrosine derivative; phenols | chromogenic compound |
| rosiglitazone | aminopyridine; thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug | |
| sr141716 | amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles | anti-obesity agent; appetite depressant; CB1 receptor antagonist | |
| ibuprofen, (r)-isomer | ibuprofen | ||
| fasudil hydrochloride | fasudil hydrochloride : A hydrochloride obtained by reaction of fasudil with one equivalent of hydrochloric acid. | hydrochloride | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; neuroprotective agent; nootropic agent; vasodilator agent |
| n-demethyllysergic acid diethylamide | N-demethyllysergic acid diethylamide: RN given refers to (betaa)-isomer | ||
| ketoprofen | |||
| tak 779 | |||
| krh 1636 | KRH 1636: structure in first source | ||
| amd 8664 | |||
| bx 471 | BX 471: a CC chemokine receptor-1 antagonist; structure in first source | ||
| dexketoprofen | dexketoprofen : A monocarboxylic acid that is (S)-hydratropic acid substituted at position 3 on the phenyl ring by a benzoyl group. A cyclooxygenase inhibitor, it is used to relieve short-term pain, such as muscular pain, dental pain and dysmenorrhoea. | benzophenones; monocarboxylic acid | cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug |
| aplaviroc | aplaviroc: a spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1; structure in first source | ||
| maraviroc | tropane alkaloid | ||
| vicriviroc | vicriviroc: structure in first source | (trifluoromethyl)benzenes | |
| sb 225002 | nitrophenol | ||
| tak-220 | TAK-220: structure in first source | ||
| cyclo(d-tyrosyl-arginyl-arginyl-3-(2-naphthyl)alanyl-glycyl) | oligopeptide | ||
| quercetin | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | |
| cp 481715 | quinoxaline-2-carboxylic acid (4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyloctyl)amide: a CCR1 antagonist and NSAID; structure in first source | ||
| bay 11-7085 | BAY11-7085 : A sulfone that is benzene substituted by [(E)-2-cyanoethenyl]sulfonyl and tert-butyl groups at position 1 and 4, respectively. It is an irreversible inhibitor of IkappaB-alpha phosphorylation in cells (IC50 = 10 muM) and prevents the activation of NF-kappaB. | benzenes; nitrile; sulfone | anti-inflammatory agent; antibacterial agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; ferroptosis inducer; NF-kappaB inhibitor |
| ancriviroc | Ancriviroc: CCR5 receptor antagonist | aromatic carboxylic acid; pyridinemonocarboxylic acid | |
| variecolin | variecolin: structure in first source | enal; sesterterpenoid | Aspergillus metabolite |
| ucb 35625 | UCB 35625: J-113863 is the (trans)-isomer; structure in first source | ||
| reparixin | reparixin: inhibits CXCR1 to prevent polymorphonuclear cell recruitment | monoterpenoid | |
| sb 297006 | SB 297006: a CC chemokine receptor-3 antagonist that inhibits binding of eotaxin and monocyte chemotactic protein-4 to eosinophils; structure in first source | ||
| sb 265610 | |||
| sch 527123 | |||
| vuf 2274 | 5-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenylpentanenitrile: an inverse agonist of human cytomegalovirus; structure in first source | ||
| rs 504393 | RS 504393: structure in first source | 1,3-oxazoles | |
| incb3344 | INCB3344: potent and selective small molecule CCR2 chemokine receptor antagonist | ||
| ccx282-b | CCX282-B: antagonist of CCR9 chemokine receptor | ||
| sb 328437 | SB 328437: a CC chemokine receptor-3 antagonist that inhibits binding of eotaxin and monocyte chemotactic protein-4 to eosinophils; structure in first source | ||
| sb 656933 | |||
| amd 070 | mavorixafor: a derivative of AMD3100; a CXCR4 blocker | aminoquinoline | |
| cenicriviroc | cenicriviroc : A member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). cenicriviroc: an inhibitor of HIV-1 | aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide | anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist |
| incb 3284 | INCB 3284: a CCR2 receptor antagonist | ||
| wz 811 | |||
| azd8309 | AZD8309: CXCR2 inhibitor | ||
| a 803467 | A 803467: an Nav1.8 sodium channel blocker; structure in first source | ||
| tn14003 | TN14003: synthetic antagonist 14-mer peptide inhibiting metastasis in an animal model | ||
| gsk1325756 | danirixin: structure in first source | ||
| amg 487 | |||
| n-(carbamoylmethyl)-3-trifluoromethyl benzamido-4-chlorobenzyl 3-aminopyrrolidine | |||
| 19,20-epoxycytochalasin q | 19,20-epoxycytochalasin Q: from Xylaria sp.; structure in first source | ||
| raltegravir | 1,2,4-oxadiazole; dicarboxylic acid amide; hydroxypyrimidine; monofluorobenzenes; pyrimidone; secondary carboxamide | antiviral drug; HIV-1 integrase inhibitor | |
| fuscin | fuscin: antibacterial pigment produced by the fungus Didiodendron fuscom; minor descriptor (75-82); online & Index Medicus search BENZOPYRANS (75-82) |